http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 05:19:03 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Caribou+Biosciences+Inc.+%28CRBU%29+PT+Lowered+to+%245+at+BofA+Securities/26923592.html BofA Securities analyst Alec W. Stranahan lowered the price target on Caribou Biosciences Inc. (NASDAQ: CRBU) to $5.00 (from $6.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Caribou+Biosciences+Inc.+%28CRBU%29+PT+Lowered+to+%245+at+BofA+Securities/26923592.html Fri, 14 Aug 2026 05:19:03 -0400 CRBU http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Caribou+Biosciences%2C++++++For%3A+Jun+30/26921177.html si-local-file:///var/storage/secattach/20260813/26921177.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Caribou+Biosciences%2C++++++For%3A+Jun+30/26921177.html Thu, 13 Aug 2026 16:12:00 -0400 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Caribou+Biosciences%2C++++++For%3A+Jun+30/26921177.html si-local-file:///var/storage/secattach/20260813/26921177.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Caribou+Biosciences%2C++++++For%3A+Jun+30/26921177.html Thu, 13 Aug 2026 16:12:00 -0400 CRBU O.51128759 http://www.streetinsider.com/Earnings/Caribou+Biosciences%2C+Inc.+%28CRBU%29+Tops+Q2+EPS+by+7c/26920949.html <p>Caribou Biosciences, Inc. (NASDAQ: CRBU) reported Q2 EPS of ($0.24), $0.07 better than the analyst estimate of ($0.31).</p><p>For earnings history and earnings-related data on Caribou Biosciences, Inc. (CRBU) <a href="http://www.streetinsider.com/ec_earnings.php?q=CRBU">click here</a>.</p> http://www.streetinsider.com/Earnings/Caribou+Biosciences%2C+Inc.+%28CRBU%29+Tops+Q2+EPS+by+7c/26920949.html Thu, 13 Aug 2026 16:09:28 -0400 CRBU http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Aug+13/26920985.html si-local-file:///var/storage/secattach/20260813/26920985.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Aug+13/26920985.html Thu, 13 Aug 2026 16:09:00 -0400 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Aug+13/26920985.html si-local-file:///var/storage/secattach/20260813/26920985.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Aug+13/26920985.html Thu, 13 Aug 2026 16:09:00 -0400 CRBU O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html <p align="center"><em>-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL --</em></p> <p align="center"><em>-- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 --</em></p> <p>BERKELEY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 CRBU O.20026344 O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html <p align="center"><em>-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL --</em></p> <p align="center"><em>-- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 --</em></p> <p>BERKELEY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 CRBU O.20026344 O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html <p align="center"><em>-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL --</em></p> <p align="center"><em>-- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 --</em></p> <p>BERKELEY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 CRBU O.20026344 O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html <p align="center"><em>-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL --</em></p> <p align="center"><em>-- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 --</em></p> <p>BERKELEY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 CRBU O.20026344 O.51128759 http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html <p align="center"><em>-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL --</em></p> <p align="center"><em>-- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 --</em></p> <p>BERKELEY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 CRBU O.20026344 O.51128759 http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html <p align="center"><em>-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL --</em></p> <p align="center"><em>-- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 --</em></p> <p>BERKELEY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 CRBU O.20026344 O.51128759 http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html <p align="center"><em>-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL --</em></p> <p align="center"><em>-- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 --</em></p> <p>BERKELEY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 CRBU O.20026344 O.51128759 http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html <p align="center"><em>-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL --</em></p> <p align="center"><em>-- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 --</em></p> <p>BERKELEY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26920796.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 CRBU O.20026344 O.51128759 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26820060.html si-local-file:///var/storage/secattach/20260727/26820060.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26820060.html Mon, 27 Jul 2026 16:28:00 -0400 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26820060.html si-local-file:///var/storage/secattach/20260727/26820060.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Caribou+Biosciences%2C+++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26820060.html Mon, 27 Jul 2026 16:28:00 -0400 CRBU O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+to+Participate+in+the+H.C.+Wainwright+4th+Annual+Cell+Therapy+Virtual+Conference/26702331.html <p>BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=44jr4_NylWTvCB5sybRARTvlxqbTgADeOOMK7dTiGPSjl2FOnPaXXcdu35Fzu0ycnhKOmpDdBh-wKX6hvHJXb5V2Oc2jzc313NyyM_Lyp6g=" rel="nofollow" target="_blank">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET.</p> <p>For more information and a link to the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=TSi0qJlL8RnJ2htAoqe0pdqBrvnRNYtq6sa4KtXlrwwnUarxdZkxaSqZEItmeMj145daCgrZBHnAYd3BJ2eJ6jc1_pmrHVXFkB-gAL5F2CsdE0729LwJ8ixt_d_ElUuUDeUSbSWDCt1e42K61zSZTQ==" rel="nofollow" target="_blank">webcast</a>, visit the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vXU5XWDGF35xzl0CrwBUZE0fnnWZoOf6VTgnRxfX868ACF0B7UyYwiqJTkuzw584DoBmaS_mpg1eUBWWRYDARX0krDDvIu-dvmxA3Z6BBtmYvdnorI7DaQeF4-bWZzQn" rel="nofollow" target="_blank">Events</a> page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+to+Participate+in+the+H.C.+Wainwright+4th+Annual+Cell+Therapy+Virtual+Conference/26702331.html Mon, 29 Jun 2026 08:00:00 -0400 CRBU O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+to+Participate+in+the+H.C.+Wainwright+4th+Annual+Cell+Therapy+Virtual+Conference/26702331.html <p>BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=44jr4_NylWTvCB5sybRARTvlxqbTgADeOOMK7dTiGPSjl2FOnPaXXcdu35Fzu0ycnhKOmpDdBh-wKX6hvHJXb5V2Oc2jzc313NyyM_Lyp6g=" rel="nofollow" target="_blank">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET.</p> <p>For more information and a link to the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=TSi0qJlL8RnJ2htAoqe0pdqBrvnRNYtq6sa4KtXlrwwnUarxdZkxaSqZEItmeMj145daCgrZBHnAYd3BJ2eJ6jc1_pmrHVXFkB-gAL5F2CsdE0729LwJ8ixt_d_ElUuUDeUSbSWDCt1e42K61zSZTQ==" rel="nofollow" target="_blank">webcast</a>, visit the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vXU5XWDGF35xzl0CrwBUZE0fnnWZoOf6VTgnRxfX868ACF0B7UyYwiqJTkuzw584DoBmaS_mpg1eUBWWRYDARX0krDDvIu-dvmxA3Z6BBtmYvdnorI7DaQeF4-bWZzQn" rel="nofollow" target="_blank">Events</a> page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+to+Participate+in+the+H.C.+Wainwright+4th+Annual+Cell+Therapy+Virtual+Conference/26702331.html Mon, 29 Jun 2026 08:00:00 -0400 CRBU O.51128759 http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+to+Participate+in+the+H.C.+Wainwright+4th+Annual+Cell+Therapy+Virtual+Conference/26702331.html <p>BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=44jr4_NylWTvCB5sybRARTvlxqbTgADeOOMK7dTiGPSjl2FOnPaXXcdu35Fzu0ycnhKOmpDdBh-wKX6hvHJXb5V2Oc2jzc313NyyM_Lyp6g=" rel="nofollow" target="_blank">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET.</p> <p>For more information and a link to the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=TSi0qJlL8RnJ2htAoqe0pdqBrvnRNYtq6sa4KtXlrwwnUarxdZkxaSqZEItmeMj145daCgrZBHnAYd3BJ2eJ6jc1_pmrHVXFkB-gAL5F2CsdE0729LwJ8ixt_d_ElUuUDeUSbSWDCt1e42K61zSZTQ==" rel="nofollow" target="_blank">webcast</a>, visit the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vXU5XWDGF35xzl0CrwBUZE0fnnWZoOf6VTgnRxfX868ACF0B7UyYwiqJTkuzw584DoBmaS_mpg1eUBWWRYDARX0krDDvIu-dvmxA3Z6BBtmYvdnorI7DaQeF4-bWZzQn" rel="nofollow" target="_blank">Events</a> page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+to+Participate+in+the+H.C.+Wainwright+4th+Annual+Cell+Therapy+Virtual+Conference/26702331.html Mon, 29 Jun 2026 08:00:00 -0400 CRBU O.51128759 http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+to+Participate+in+the+H.C.+Wainwright+4th+Annual+Cell+Therapy+Virtual+Conference/26702331.html <p>BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=44jr4_NylWTvCB5sybRARTvlxqbTgADeOOMK7dTiGPSjl2FOnPaXXcdu35Fzu0ycnhKOmpDdBh-wKX6hvHJXb5V2Oc2jzc313NyyM_Lyp6g=" rel="nofollow" target="_blank">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET.</p> <p>For more information and a link to the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=TSi0qJlL8RnJ2htAoqe0pdqBrvnRNYtq6sa4KtXlrwwnUarxdZkxaSqZEItmeMj145daCgrZBHnAYd3BJ2eJ6jc1_pmrHVXFkB-gAL5F2CsdE0729LwJ8ixt_d_ElUuUDeUSbSWDCt1e42K61zSZTQ==" rel="nofollow" target="_blank">webcast</a>, visit the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vXU5XWDGF35xzl0CrwBUZE0fnnWZoOf6VTgnRxfX868ACF0B7UyYwiqJTkuzw584DoBmaS_mpg1eUBWWRYDARX0krDDvIu-dvmxA3Z6BBtmYvdnorI7DaQeF4-bWZzQn" rel="nofollow" target="_blank">Events</a> page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+to+Participate+in+the+H.C.+Wainwright+4th+Annual+Cell+Therapy+Virtual+Conference/26702331.html Mon, 29 Jun 2026 08:00:00 -0400 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Jun+17/26665825.html si-local-file:///var/storage/secattach/20260618/26665825.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Jun+17/26665825.html Thu, 18 Jun 2026 16:02:00 -0400 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Jun+17/26665825.html si-local-file:///var/storage/secattach/20260618/26665825.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Jun+17/26665825.html Thu, 18 Jun 2026 16:02:00 -0400 CRBU O.51128759 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Caribou+Biosciences+Inc.+%28CRBU%29/26650138.html <p>H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $11.00 price target on Caribou Biosciences Inc. (NASDAQ: CRBU).</p><p>The analyst commented: "At EHA, Caribou presented updated data from the ANTLER trial, which is evaluating vispa-cel (CB-010) in 2L+ CD19-targeted therapy-naive LBCL patients. As seen in the presentation, a single dose of 80×106 optimized vispa-cel CAR-T cells—defined as cells from a donor <30 years old with >2 matched HLA alleles between patient and donor—achieved an 82% ORR (67% CR) and a 17.1-month mPFS in 27 2L LBCL patients. These results are noteworthy for two key reasons. First, vispa-cel’s 17.1-month mPFS exceeds http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Caribou+Biosciences+Inc.+%28CRBU%29/26650138.html Tue, 16 Jun 2026 06:48:37 -0400 CRBU http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX